New drug shows promise for lung cancer brain metastases

NCT ID NCT05465343

Completed Disease control Sponsor: Peking Union Medical College Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the drug furmonertinib in 24 people with advanced non-small cell lung cancer (NSCLC) that has EGFR mutations and spread to the brain. The goal was to see how long the drug could keep brain tumors from growing. Participants took a daily pill, and researchers measured brain tumor response and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Furmonertinib
What this could lead to: If successful, furmonertinib could offer a new treatment option for patients with advanced lung cancer that has spread to the brain, potentially controlling the disease longer.
What could go wrong: This is a small, early-phase trial with only 24 participants and no comparison group. Results may not apply to all patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES EGFR MUTATION FURMONERTINIB NSCLC

Contacts and locations

Show contact details

Locations

Ethics Committee

Beijing, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.